Trial Profile
Comparison of efficacy and safety of secondary treatment with increased fesoterodine and with mirabegron combination with 4mg fesoterodine for those who still have moderate or more overactive bladder symptoms after initial treatment with 4mg fesoterodine: preliminary study
Status:
Not yet recruiting
Phase of Trial:
Phase II
Latest Information Update: 20 Sep 2022
Price :
$35
*
At a glance
- Drugs Fesoterodine (Primary) ; Mirabegron (Primary)
- Indications Overactive bladder
- Focus Therapeutic Use
- 22 Sep 2013 New trial record